Promising drug combo targets rare leukemia with poor prognosis
NCT ID NCT05901974
First seen Jan 04, 2026 · Last updated May 13, 2026 · Updated 19 times
Summary
This study tests whether combining two drugs, venetoclax and azacitidine, can help people with a rare type of acute leukemia that is hard to treat. About 23 newly diagnosed patients aged 15 and older will receive the treatment to see if it improves remission rates. The goal is to find a more effective option for this aggressive disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affliated Hospital of Soochow University
RECRUITINGSuzhou, China
Contact
Conditions
Explore the condition pages connected to this study.